• 1
    Vaishampayan U, Glode M, Du W, et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000; 6: 4205-4208.
  • 2
    Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006; 17: 114-124.
  • 3
    Nilsson R, Lindgren L, Lilliehorn P. Extracorporeal immunoadsorption therapy on rats. In vivo depletion of specific antibodies. Clin Exp Immunol. 1990; 82: 440-444.
  • 4
    Garkavij M, Tennvall J, Strand SE, et al. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method. Acta Oncol. 1996; 35: 309-312.
  • 5
    Martensson L, Nilsson R, Sjogren HO, Strand SE, Tennvall J. A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats. Artif Organs. 2007; 31: 312-316.
  • 6
    Kurkus J, Nilsson R, Linden O, Schonstrom N, Sandberg BE, Tennvall J. Biocompatibility of a novel avidin-agarose adsorbent for extracorporeal removal of redundant radiopharmaceutical from the blood. Artif Organs. 2007; 31: 208-214.
  • 7
    Linden O, Kurkus J, Garkavij M, et al. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biother Radiopharm. 2005; 20: 457-466.
  • 8
    Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. J Nucl Med. 2007; 48: 269-276.
  • 9
    Nemecek ER, Green DJ, Fisher DR, et al. Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies. Cancer Biother Radiopharm. 2008; 23: 181-191.
  • 10
    Sjogren HO, Isaksson M, Willner D, Hellstrom I, Hellstrom KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res. 1997; 57: 4530-4536.
  • 11
    Pass D, Freeth G. The rat. ANZCCART News. 1993; 6: 1-4.
  • 12
    Sun MM, Beam KS, Cerveny CG, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem. 2005; 16: 1282-1290.
  • 13
    Martensson L, Wang Z, Nilsson R, et al. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clin Cancer Res. 2005; 11( pt 2): 7104s-7108s.
  • 14
    Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008; 26: 925-932.